A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis

Registry ID

EUCTR2018-004176-35

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Aristea Therapeutics Inc.

Start date

2019-04-10

Last update

2026-08-16

Conditions

• Palmoplantar Pustulosis

Summary

The primary objective is: • To assess the efficacy of RIST4721 versus placebo in adult subjects with moderate to severe palmoplantar pustulosis (PPP) using a range of efficacy endpoints

Locations

• , , Germany

Related clinical trials

• A phase 3, randomized, double-blind, placebo-controlled, multicenter study with open-label extension to evaluate the efficacy and safety of bimekizumab in study participants with palmoplantar pustulosis
• A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
• Picankibart in Palmoplantar Pustulosis
• Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers

View on source registry